Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 11, Number 6—June 2005

Dispatch

Macrolide- and Telithromycin-resistant Streptococcus pyogenes, Belgium, 1999–20031

Surbhi Malhotra-Kumar*Comments to Author , Christine Lammens*, Sabine Chapelle*, Monique Wijdooghe*, Jasper Piessens*, Koen Van Herck*, and Herman Goossens*
Author affiliations: *University of Antwerp, Antwerp, Belgium

Main Article

Table A1

In vitro activity of 6 antimicrobial agents against macrolide-resistant Streptococcus pyogenes phenotypes during 1999–2003

Antimicrobial* Constitutive (n = 209)
M (n = 279)
Inducible (n = 18)
Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90
Erythromycin 4–>512 >512 >512 1–128 8 16 1–>512 4 >512
Clindamycin 2–>512 >512 >512 ≤0.03–4 0.06 1 0.125–256 0.75 128
Clarithromycin 1–>512 >512 >512 1–256 8 16 0.5–>512 2 >512
Azithromycin 4–>512 >512 >512 1–128 8 16 0.5–>512 4 >512
Tetracycline 0.06–128 32 64 ≤0.03–64 0.25 0.5 0.06–64 0.5 64
Telithromycin† 0.0075–32 1 8 0.0075–2 0.5 0.5 0.003–4 0.06 0.5

*Dilution range of 0.03 to 512 μg/mL for all antimicrobial agents except telithromycin, which is 0.00375 to 64 μg/mL.
†Breakpoints for telithromycin, susceptible ≤1μg/mL, resistant ≥4 μg/mL.

Main Article

1A preliminary account of this work was presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30–November 2, 2004, Washington DC, USA.

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO